Recombinant multi-species SMMHC/MYH11 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine SMMHC/MYH11 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
The protein encoded by this gene is a smooth muscle myosin belonging to the myosin heavy chain family. The gene product is a subunit of a hexameric protein that consists of two heavy chain subunits and two pairs of non-identical light chain subunits. It functions as a major contractile protein, converting chemical energy into mechanical energy through the hydrolysis of ATP. A chromosomal rearrangement involving this gene is associated with acute myeloid leukemia of the M4Eo subtype. Mutations in this gene are associated with visceral myopathy, megacystis-microcolon-intestinal hypoperistalsis syndrome 2, and familial thoracic aortic aneurysm 4. [provided by RefSeq, May 2022]
The Alternative Names of target: AAT4,FAA4,MYH11,Myh11,Myosin heavy chain,Myosin heavy chain 11,Myosin-11,SM1,SM2,SMHC,SMMHC,SMMS-1,VSCM2,smMHC,smooth muscle isoform

Target products collectionGo to SMMHC/MYH11 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No. Product Name Species Reactivity
GM-Tg-hg-IP2614-Ag-1/ GM-Tg-hg-IP2614-Ag-2 Human SMMHC/MYH11 protein Human
GM-Tg-rg-IP2614-Ag-1/ GM-Tg-rg-IP2614-Ag-2 Rat SMMHC/MYH11 protein Rat
GM-Tg-mg-IP2614-Ag-1/ GM-Tg-mg-IP2614-Ag-2 Mouse SMMHC/MYH11 protein Mouse
GM-Tg-cynog-IP2614-Ag-1/ GM-Tg-cynog-IP2614-Ag-2 Cynomolgus/Rhesus macaque SMMHC/MYH11 protein Cynomolgus/ Rhesus macaque
GM-Tg-felg-IP2614-Ag-1/ GM-Tg-felg-IP2614-Ag-2 Feline SMMHC/MYH11 protein Feline
GM-Tg-cang-IP2614-Ag-1/ GM-Tg-cang-IP2614-Ag-2 Canine SMMHC/MYH11 protein Canine
GM-Tg-bovg-IP2614-Ag-1/ GM-Tg-bovg-IP2614-Ag-2 Bovine SMMHC/MYH11 protein Bovine
GM-Tg-equg-IP2614-Ag-1/ GM-Tg-equg-IP2614-Ag-2 Equine SMMHC/MYH11 protein Equine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No. GM-Tg-hg-IP2614-Ag-1/ GM-Tg-hg-IP2614-Ag-2; GM-Tg-rg-IP2614-Ag-1/ GM-Tg-rg-IP2614-Ag-2;
GM-Tg-mg-IP2614-Ag-1/ GM-Tg-mg-IP2614-Ag-2; GM-Tg-cynog-IP2614-Ag-1/ GM-Tg-cynog-IP2614-Ag-2;
GM-Tg-felg-IP2614-Ag-1/ GM-Tg-felg-IP2614-Ag-2; GM-Tg-cang-IP2614-Ag-1/ GM-Tg-cang-IP2614-Ag-2;
GM-Tg-bovg-IP2614-Ag-1/ GM-Tg-bovg-IP2614-Ag-2; GM-Tg-equg-IP2614-Ag-1/ GM-Tg-equg-IP2614-Ag-2
Products Name SMMHC/MYH11 protein
Species Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine
Target Name SMMHC/MYH11
Protein Sub-location Introcelluar Protein
Isotypes Recombinant protein
Expression platform Mammalian cell
Bioactivity validation Affintiy&bioactivity validated by ELISA, cell culture validated.
Tag His
Products description Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine SMMHC/MYH11 protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Purity Purity: ≥95% (SDS-PAGE)
Application In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference






    About Gmab

    GDU
    GDU

    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.